Merck licenses KRAS G12D inhibitor from Tao Hu for $400 million upfront
read at Endpoints ↗DealNeutral
Merck has signed a licensing agreement for a KRAS G12D inhibitor, providing an upfront payment of $400 million.
The deal follows a 2023 transaction in which the same entrepreneur, synthetic chemist Tao Hu, sold a KRAS G12D inhibitor to AstraZeneca.
The newly licensed molecule is described as having a twist that could set it apart from earlier candidates, though details were not disclosed in the brief report.
The agreement highlights Merck's ongoing commitment to expanding its pipeline of targeted cancer therapies.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Merck licenses a KRAS G12D inhibitor for $400M upfront”
read at Endpoints ↗80 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that